

Amendments to the Claims:

1. (Currently Amended) A sustained release oral ~~matrix tablet dosage form~~ comprising:
a ~~single functional layer; and~~
optionally, ~~one or more nonfunctional layers adjacent to the single functional layer;~~
wherein the ~~single functional layer comprises~~ alfuzosin or pharmaceutically acceptable salt, solvate, enantiomers or mixtures thereof, and ~~one or more~~ a release-retarding ~~agent ingredients~~ comprises in combination hydroxypropylmethyl cellulose and hydroxypropyl cellulose.
2. (Cancelled)
3. (Cancelled)
4. (Cancelled)
5. (Currently Amended) The sustained release ~~tablet dosage form~~ of claim 1, wherein the ~~tablet single functional layer~~ further comprises one or more pharmaceutically acceptable excipients.
6. (Currently Amended) The sustained release ~~tabletoral dosage form~~ of claim 1, wherein the one or more pharmaceutically acceptable excipients comprise one or more of binders, diluents, and lubricants/glidants.
7. (Currently Amended) The sustained release ~~tabletoral dosage form~~ of claim 6, wherein the binders comprise one or more of polyvinyl pyrrolidone, pregelatinized starch, and gelatin.
8. (Currently Amended) The sustained release ~~tabletoral dosage form~~ of claim 6, wherein the diluents comprise one or more of lactose, mannitol, and microcrystalline cellulose.

9. (Currently Amended) The sustained release ~~tabletoral dosage form~~ of claim 6, wherein the lubricants comprise one or more of magnesium stearate, zinc stearate, talc, and colloidal silicon dioxide.
10. (Currently Amended) The sustained release ~~tabletoral dosage form~~ of claim 1, wherein the ~~tablet functional layer~~ comprises between about 10% to about 90% w/w of hydroxypropyl methylcellulose and between about 10% to about 90% w/w of hydroxypropyl cellulose.
11. (Cancelled)
12. (Cancelled)
13. (Cancelled)
14. (Cancelled)
15. (Cancelled)
16. (Cancelled)
17. (Cancelled)
18. (Currently Amended) The sustained release ~~tabletoral dosage form~~ of claim 1, further comprising wherein the one or more nonfunctional layers surrounding the tablet adjacent to the single functional layer comprises a cosmetic coating.
19. (Cancelled)
20. (Cancelled)
21. (Cancelled)
22. (Cancelled)
23. (Cancelled)
24. (Cancelled)
25. (Cancelled)

26. (Cancelled)
27. (Cancelled)
28. (Cancelled)
29. (Currently Amended) A process for forming a sustained release oral matrix tablet~~dosage form~~, the process comprising:
- forming a mixture of alfuzosin or pharmaceutically acceptable salt, solvate, enantiomers or mixtures thereof and ~~a one or more~~ release-retarding agent comprising ingredients;
- compressing the mixture into a tablet~~forming a dosage form having a single functional layer from the mixture~~; and
- optionally coating the tablet with~~forming one or more nonfunctional layers adjacent to the single functional layer~~.
30. (Cancelled)
31. (Cancelled)
32. (Cancelled)
33. (Cancelled)
34. (Cancelled)
35. (Currently Amended I) The process of claim 29, wherein ~~the forming a mixture is granulated by comprises one or more of direct compression, wet granulation or, and dry granulation~~.
36. (Cancelled)
37. (Currently Amended) The process of claim 29, wherein forming a mixture further comprises ~~adding one or more pharmaceutically acceptable excipients to the mixture~~.
38. (Cancelled)

39. (Cancelled)

40. (Cancelled)